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ABSTRACT
Objectives Systemic lupus erythematosus (SLE; OMIM
152700) is characterised by the production of antibodies
to nuclear antigens. We previously identiﬁed variants in
complement receptor 2 (CR2/CD21) that were associated
with decreased risk of SLE. This study aimed to identify
the causal variant for this association.
Methods Genotyped and imputed genetic variants
spanning CR2 were assessed for association with SLE in
15 750 case-control subjects from four ancestral groups.
Allele-speciﬁc functional effects of associated variants
were determined using quantitative real-time PCR,
quantitative ﬂow cytometry, electrophoretic mobility shift
assay (EMSA) and chromatin immunoprecipitation (ChIP)-
PCR.
Results The strongest association signal was detected
at rs1876453 in intron 1 of CR2 ( pmeta=4.2×10
−4, OR
0.85), speciﬁcally when subjects were stratiﬁed based on
the presence of dsDNA autoantibodies (case-control
pmeta=7.6×10
−7, OR 0.71; case-only pmeta=1.9×10
−4,
OR 0.75). Although allele-speciﬁc effects on B cell CR2
mRNA or protein levels were not identiﬁed, levels of
complement receptor 1 (CR1/CD35) mRNA and protein
were signiﬁcantly higher on B cells of subjects
harbouring the minor allele (p=0.0248 and p=0.0006,
respectively). The minor allele altered the formation of
several DNA protein complexes by EMSA, including one
containing CCCTC-binding factor (CTCF), an effect that
was conﬁrmed by ChIP-PCR.
Conclusions These data suggest that rs1876453 in
CR2 has long-range effects on gene regulation that
decrease susceptibility to lupus. Since the minor allele at
rs1876453 is preferentially associated with reduced risk
of the highly speciﬁc dsDNA autoantibodies that are
present in preclinical, active and severe lupus,
understanding its mechanisms will have important
therapeutic implications.
INTRODUCTION
Systemic lupus erythematosus (SLE (OMIM
152700)) is a heterogeneous autoimmune disease
with a strong genetic component modiﬁed by envir-
onmental exposures. The complement system has
been linked to its pathogenesis since low serum
complement levels were ﬁrst demonstrated in
patients with active disease.1 2 Although comple-
ment activation resulting in tissue damage is an
important feature of lupus, deﬁciencies of early
classical complement pathway components are
paradoxically strongly associated with lupus suscep-
tibility. Deﬁciencies or altered function of comple-
ment receptors have also been associated with
lupus in humans and murine models of disease.3–5
These effects have been attributed to alterations in
antigen clearance, antigen processing, tolerance
induction and cell activation, but the exact mechan-
isms remain poorly understood.
SLE is characterised by the production of
class-switched autoantibodies against nuclear anti-
gens that have undergone afﬁnity maturation, sug-
gesting their generation in germinal centre
reactions. Complement receptor 2 (CR2/CD21) is
primarily expressed on mature B cells and follicular
dendritic cells, two major components of germinal
centres. We ﬁrst showed Cr2, which encodes both
CR2 and complement receptor 1 (CR1/CD35) in
the mouse, to be a candidate gene for lupus suscep-
tibility in the NZM2410 model of lupus based on
structural and functional alterations in its gene
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products.6 We subsequently demonstrated strong association of
a common three single-nucleotide polymorphism (SNP) CR2
haplotype (rs3813946 in the 50UTR, rs1048971 and rs17615 in
exon 10) with increased risk of lupus susceptibility
(p=1.0×10−5) in Caucasian and Chinese lupus simplex families
with a 1.54-fold increased risk for disease development.7 We
conﬁrmed this in a case-control analysis of an independent
European-derived population (p=2.3×10−2, OR 1.1 (95% CI
1.02 to 1.2))8 and also showed that a haplotype formed by the
minor alleles of three SNPs in exons 10 and 11 (rs1048971,
rs17615, rs4308977) was associated with decreased risk of
lupus (p=1.6×10−2, OR 0.90 (95% CI 0.82 to 0.98)).8
In this study, we ﬁne-mapped the region spanning CR2 in
15 750 subjects from four ancestral groups to identify potential
causal variant(s) for these associations with lupus. Additionally,
we explored the association of CR2 polymorphisms with clinical
manifestations of lupus in order to generate new hypotheses
regarding how CR2 contributes to disease development.
METHODS
Subjects
DNA from individuals recruited from multiple sites was pro-
cessed at the Oklahoma Medical Research Foundation (OMRF;
Large Lupus Association Study 2) with institutional review
board approval. All patients with SLE met the 1997 American
College of Rheumatology revised classiﬁcation criteria.9 Clinical
data were collected by chart review or testing in the OMRF
Clinical Immunology laboratory. Samples for functional analyses
were from healthy non-smoking 18-year-old to 60-year-old
adults without family history of autoimmune disease at the
University of Colorado School of Medicine.
Genotyping
Genotyping was performed on the OMRF Illumina iSelect plat-
form.10 11 Subjects with missing genotype rate >10%, shared
identical by descent >0.4 or gender mismatch were removed.
Global ancestry was estimated based on the genotype of ances-
try informative markers (AIMs), using principal components
analysis12 and ADMIXMAP13 as described14 and genetic out-
liers removed. Final clean data were from European Americans
(EA), African Americans (AA; 7.5% Gullahs), Asians (AS;
74.6% Koreans, 16.1% Chinese, 9.3% Japanese and
Singaporeans) and Hispanics (HS) enriched for Amerindian–
European admixture. 2001 EA cases and 2153 EA controls were
previously analysed.8 Subjects for functional studies were geno-
typed using a Taqman SNP Genotyping Assay.
Imputation
SNP and insertion-deletion (INDEL) genotypes of 379
Europeans, 246 Africans, 286 Asians and 181 Americans from
the 1000 Genomes Project (V.3, Phase 1 integrated data, March
2012 release) were references in imputation for EA, AA, AS and
HS subjects, respectively. Imputation was performed using
IMPUTE 2.1.215; genotypes with information scores >0.9 and
minor allele frequency (MAF)>0.01 were further analysed.
Association tests
SNPs and INDELs showing biased Hardy–Weinberg equilibrium
(p<0.01 in controls, p<0.0001 in cases), missing genotype rate
>5% or different missing genotype rates between cases and
controls (rate >2% and p<0.05) were excluded. Variants were
assessed for association with SLE under a logistic regression
model, and haplotypic and haplotype-based conditional associ-
ation tests were performed, adjusting for gender and the ﬁrst
three principal components estimated using AIMs. For transan-
cestral meta-analysis, a ﬁxed effect model was applied if
Cochran’s Q statistic showed no evidence of genetic heterogen-
eity among ORs (p>0.05); otherwise, a random effect model
was used. Analyses were performed using PLINK V.1.07.16
Sample preparation
Peripheral blood mononuclear cells (PBMC) were isolated over
Ficoll–Paque (Sigma–Aldrich). DNA was puriﬁed using the
QIAamp DNA Mini Kit (QIAgen). B cells were puriﬁed using
the Easy Sep Human B Cell Enrichment Kit (StemCell
Technologies). RNA was processed using the RNeasy Plus Mini
Kit (QIAgen). Quality check and quantiﬁcation of RNAwas per-
formed using the Agilent 2100 Bioanalyzer. RNA and DNA
were stored at −70°C. Epstein–Barr virus (EBV)-transformed B
cell lines were generated by incubating PBMCs with supernatant
from cell line GM7404A and cyclosporine A.
qPCR and quantitative ﬂow cytometry
qPCR of primary B cell transcripts was performed using cDNA
transcribed using random primers and MultiScribe reverse tran-
scriptase (Applied Biosystems), customised CR2 primers
(50-CGAGAAGTATATTCTGTTGATCCATACAA-30, 50-CTAATC
AATATTCCGCTGAATTCCA-30) and probe (6FAM-AACTGG
TGTGTGCCTCA-MGBNFQ), Taqman assays for CR1
(4331182) and β-actin (4352935E), and the Applied Biosystems
7500 Real-Time PCR System. Relative expression levels of CR2
and CR1, normalised to β-actin, were calculated using the com-
parative CT method.
17
Quantitative ﬂow cytometry was performed using Quantum
Simply Cellular microbeads (Bangs Laboratories). Puriﬁed B
cells were incubated with ethidium monoazide to exclude dead
cells and mouse IgG to block Fc receptors and stained with bio-
tinylated anti-human CD19 (clone HD37) followed by
AF405-labelled streptavidin (Molecular Devices) and either
AF488-labelled anti-human CR1 (clone 6B1.H12) or
AF488-labelled anti-human CR2 (clone THB5, Harlan). Data
acquired on ﬁxed cells within 24 h using the LSR II and
CellQuest software (BD Biosciences) were analysed with FlowJo
(Tree Star).




HPLC-puriﬁed and biotin-labelled; 25 fmol labelled oligonu-
cleotides were incubated with 2–4 μg nuclear extracts (NE) or
50 mM potassium chloride (for unbound controls) in 4% Ficoll,
20 mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid
(HEPES), 1 mM EDTA, 0.5 mM dithiothreitol and 1 mg poly
dI:dC for 30 min on ice. For competition and blocking experi-
ments, NE were pre-incubated with unlabelled oligonucleotide
or anti-CCCTC-binding factor (CTCF) (sc-15914; Santa Cruz
Biotechnology) for 10 or 30 min on ice. Reactions were electro-
phoresed on 6% DNA retardation gels (Life Technologies),
transferred and cross-linked using ultraviolet light to nylon
membranes and visualised using the Chemiluminescent Nucleic
Acid Detection Module (Thermo Fisher Scientiﬁc).
Chromatin immunoprecipitation-PCR
Chromatin immunoprecipitation (ChIP) was performed using
the Upstate Biotechnology ChIP assay kit with minor modiﬁca-
tions.18 1.1×108 cells were incubated with 1% formaldehyde
for 15 min and 0.125 M glycine added for 5 min. Washed cells
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Table 1 Association of rs1876453 with 14 SLE subphenotypes
Subphenotypes
N MAF Pos vs Control Pos vs Neg
Group Pos Neg Pos Neg Control p Value OR (95% CI) p Value OR (95% CI)
Malar rash EA 2108 1171 0.088 0.087 0.099 0.11 0.89 (0.78 to 1.03) 0.92 1.01 (0.85 to 1.21)
AA 685 714 0.08 0.066 0.086 0.24 0.87 (0.69 to 1.10) 0.15 1.24 (0.92 to 1.65)
HS 836 572 0.03 0.032 0.051 3.0×10−3 0.57 (0.39 to 0.83) 0.62 0.89 (0.57 to 1.40)
Meta 5.7×10−3 0.85 0.52 1.05
Discoid rash EA 573 2486 0.088 0.088 0.099 0.38 0.91 (0.73 to 1.13) 0.98 1.00 (0.80 to 1.25)
AA 485 915 0.088 0.065 0.086 0.81 0.97 (0.75 to 1.25) 0.029 1.39 (1.04 to 1.86)
HS 180 1227 0.026 0.031 0.051 0.032 0.46 (0.22 to 0.93) 0.43 0.75 (0.37 to 1.53)
Meta 0.2 0.9 0.26 1.1
Photosensitivity EA 2345 1142 0.091 0.08 0.099 0.29 0.93 (0.82 to 1.06) 0.16 1.14 (0.95 to 1.36)
AA 685 712 0.078 0.069 0.086 0.14 0.84 (0.66 to 1.06) 0.39 1.14 (0.85 to 1.52)
HS 840 564 0.037 0.022 0.051 0.047 0.70 (0.49 to 0.99) 0.05 1.64 (1.00 to 2.67)
Meta 0.029 0.89 0.031 1.17
Oral ulcers EA 1574 1642 0.09 0.09 0.099 0.22 0.91 (0.78 to 1.06) 0.9 0.99 (0.83 to 1.17)
AA 495 903 0.059 0.081 0.086 1.7×10−3 0.63 (0.47 to 0.84) 0.06 0.74 (0.54 to 1.01)
HS 562 844 0.036 0.027 0.051 0.094 0.71 (0.48 to 1.06) 0.2 1.33 (0.85 to 2.08)
Meta 3.5×10−3 0.83 0.59 0.96
Arthritis EA 2987 619 0.088 0.091 0.099 0.075 0.89 (0.79 to 1.01) 0.76 0.97 (0.78 to 1.20)
AA 1166 232 0.076 0.059 0.086 0.048 0.82 (0.67 to 1.01) 0.19 1.33 (0.87 to 2.02)
HS 1007 402 0.031 0.031 0.051 3.7×10−3 0.60 (0.42 to 0.85) 0.96 1.01 (0.62 to 1.66)
Meta 9.9×10−4 0.84 0.76 1.03
Serositis EA 1341 2060 0.084 0.092 0.099 0.042 0.85 (0.72 to 0.99) 0.26 0.91 (0.76 to 1.08)
AA 653 742 0.07 0.076 0.086 0.025 0.75 (0.59 to 0.96) 0.55 0.92 (0.69 to 1.22)
HS 384 877 0.029 0.03 0.051 0.022 0.56 (0.34 to 0.92) 0.94 0.98 (0.58 to 1.64)
Meta 6.0×10−4 0.8 0.21 0.91
Renal disorder EA 1102 2143 0.079 0.098 0.099 0.016 0.80 (0.67 to 0.96) 0.018 0.80 (0.67 to 0.96)
AA 697 701 0.065 0.081 0.086 6.1×10−3 0.71 (0.55 to 0.91) 0.092 0.78 (0.58 to 1.04)
HS 644 746 0.032 0.028 0.051 0.029 0.64 (0.43 to 0.96) 0.41 1.21 (0.77 to 1.91)
Meta 4.4×10−5 0.75 0.013 0.83
Neurological disorder EA 575 2524 0.099 0.092 0.099 0.89 1.02 (0.82 to 1.26) 0.51 1.07 (0.87 to 1.33)
AA 372 1025 0.088 0.068 0.086 0.75 0.95 (0.72 to 1.27) 0.069 1.34 (0.98 to 1.82)
HS 194 1213 0.024 0.032 0.051 0.036 0.47 (0.23 to 0.95) 0.42 0.75 (0.37 to 1.52)
Meta 0.58 0.95 0.18 1.12
Haematological disorder EA 2173 1081 0.085 0.089 0.099 0.038 0.87 (0.76 to 0.99) 0.67 0.96 (0.80 to 1.15)
AA 1011 384 0.07 0.079 0.086 0.012 0.76 (0.62 to 0.94) 0.45 0.89 (0.65 to 1.22)
HS 811 459 0.031 0.028 0.051 9.6×10−3 0.61 (0.42 to 0.89) 0.79 1.07 (0.65 to 1.77)
Meta 1.9×10−4 0.81 0.53 0.95
Anti-dsDNA EA 1179 1500 0.071 0.104 0.099 6.6×10−4 0.73 (0.61 to 0.88) 1.2×10−4 0.68 (0.56 to 0.83)
AA 675 746 0.067 0.083 0.086 9.7×10−3 0.72 (0.56 to 0.92) 0.097 0.79 (0.59 to 1.04)
HS 726 564 0.03 0.028 0.051 7.1×10−3 0.58 (0.39 to 0.86) 0.61 1.13 (0.70 to 1.84)
Meta 7.6×10−7 0.71 1.9×10−4 0.75
Anti-Sm EA 225 2064 0.109 0.093 0.099 0.37 1.15 (0.85 to 1.56) 0.24 1.20 (0.88 to 1.64)
AA 430 755 0.087 0.076 0.086 0.78 0.96 (0.74 to 1.26) 0.41 1.14 (0.84 to 1.54)
HS 294 905 0.03 0.029 0.051 0.069 0.60 (0.35 to 1.04) 0.71 1.11 (0.63 to 1.98)
Meta 0.78 0.97 0.15 1.16
Anti-RNP EA 255 1382 0.104 0.095 0.099 0.46 1.12 (0.83 to 1.51) 0.49 1.12 (0.82 to 1.53)
AA 378 253 0.078 0.077 0.086 0.34 0.87 (0.65 to 1.16) 0.91 1.03 (0.67 to 1.57)
HS 171 443 0.024 0.04 0.051 0.033 0.44 (0.21 to 0.94) 0.16 0.57 (0.26 to 1.26)
Meta 0.45 0.93 0.86 1.02
Anti-SSA/Ro EA 450 1331 0.086 0.093 0.099 0.28 0.87 (0.68 to 1.12) 0.51 0.92 (0.70 to 1.19)
AA 292 542 0.062 0.08 0.086 0.023 0.66 (0.46 to 0.94) 0.21 0.77 (0.51 to 1.15)
HS 238 491 0.028 0.039 0.051 0.027 0.51 (0.28 to 0.93) 0.28 0.70 (0.36 to 1.34)
Meta 5.4×10−3 0.76 0.13 0.85
Anti-SSB/La EA 148 1506 0.091 0.095 0.099 0.76 0.94 (0.62 to 1.41) 0.87 0.97 (0.64 to 1.46)
AA 81 692 0.037 0.08 0.086 0.025 0.39 (0.17 to 0.89) 0.057 0.44 (0.19 to 1.03)
HS 71 558 0.042 0.033 0.051 0.63 0.81 (0.34 to 1.92) 0.53 1.33 (0.54 to 3.30)
Meta 0.18 0.79 0.5 0.89
N, number in sample; MAF, minor allele frequency; Pos, subphenotype positive; Neg, subphenotype negative; p value, p value and OR were calculated using a logistic regression model
adjusted for gender and global ancestry; EA, European–American; AA, African–American; HS, Hispanic; Meta, Meta-analysis; SLE, systemic lupus erythematosus.
p Values ≤0.05 are marked with bold italics; significant p values after Bonferroni correction were ≤3.6×10−3.
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were incubated in NP-40 lysis buffer and nuclei pelleted, resus-
pended in sodium dodecyl sulfate lysis buffer and sonicated ﬁve
times on ice. Precleared soluble chromatin was incubated with
anti-CTCF, an isotype control, or no antibody followed by
Protein G agarose/salmon sperm DNA. qPCR was performed
on immune complex-associated DNA using primers spanning
rs1876453 (50–GGAAAGTTTCTGTGCCGCGA–30, 50-GACAA
TCAGGACCAGGCGGT–30), SYBR Green-based detection, and
the Illumina Eco Real-Time PCR System. A standard curve was
constructed using a chromatin input control.
qPCR of EBV-transformed cell transcripts was performed
using cDNA transcribed using the Superscript VILO cDNA syn-
thesis kit (Life Technologies), primers speciﬁc for β-actin
(50-GATGACCCAGATCATGTTTGAG-30, 50-GACTCCATG
CCCAGGAAGGAA-30), CTCF (50-CAACCAGCCCAAACAGAA
CCAG-30, 50-TCCTCTTCCTCTCCCTCTGC-30), CR2 (50-TG
CCTGTAAAACCAACTTCTC-30, 50-AGCAAGTAACCAGATT
CACAG-30) and CR1 (50-TGCTAAGGACAGGTGCAGAC-30,
50-GGCAGACGAGGAACCAATGA-30), SYBR Green-based detec-
tion, and the Eco Real-Time PCR System (Illumina). Transcript
abundance was determined by comparison with a standard curve
and normalised to β-actin.
Statistical analysis
A two-tailed unpaired Student t test detected differences
between groups. Spearman rank correlation determined correl-
ation within a group. A p value of <0.05 was considered signiﬁ-
cant. Statistics and graphs were generated using GraphPad Prism
software.
RESULTS
Association of rs1876453 with decreased risk of lupus
To localise causal variants of the CR2 gene, we genotyped 56
SNPs in CR2 and CR1 and 347 AIMs in 15 750 unrelated case-
control subjects from four ancestral groups: EA (3872 cases vs
Figure 1 Association of single-nucleotide polymorphisms (SNPs) in the CR2 region with dsDNA autoantibodies. (A) The genomic structure of the
CR2 region and positions of genetic variants are indicated. (B) The allelic p value (-log10p value) of each genetic variant with dsDNA autoantibodies
is plotted against its position as a circle (genotyped) or a triangle (imputed) for European American (EA), African American (AA) and Hispanic (HS),
respectively. Genetic variants are highlighted using different colours according to their strength of linkage disequilibrium (LD) (r2) with rs1876453.
An arrow is used to indicate the position of rs1876453. (C) Transancestral meta-analysis p value generated using ﬁxed and random model are
highlighted as red and blue, respectively. The dashed line represents the signiﬁcance level after Bonferroni correction. (D) Frequencies, ORs and p
values of haplotypes formed by lupus-associated CR2 SNPs in various ancestral groups. Haplotype H1 corresponds to the previously reported
systemic lupus erythematosus (SLE)-associated haplotype and is highlighted in green.
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3449 controls), AA (1676 vs 1929), AS (1265 vs 1260) and HS
(1492 vs 807). Genotypes for additional variants (SNPs and
INDELs) were imputed using reference data from the 1000
Genomes Project. After applying quality control measures, 138
EA, 167 AA, 102 AS and 133 HS genetic variants deeply cover-
ing a 57.6 kB region 50 upstream of CR2 to intron 1 of CR1
were assessed for association with SLE (see online supplemen-
tary ﬁgure S1 and table S1). Only rs1876453, in intron 1 of
CR2, was consistently associated with SLE in EA (MAF 0.086 in
cases vs 0.099 in controls, p=0.045, OR 0.89 (95% CI 0.79 to
0.99)), AA (0.075 vs 0.086, p=0.045, OR 0.83 (95% CI 0.70
to 0.99)) and HS (0.032 vs 0.051, p=3.5×10−3, OR 0.62 (95%
CI 0.46 to 0.86)). rs1876453 was not associated with SLE in AS
given the low MAF in this group (0.0004 vs 0.0008, p=0.68,
OR 0.60 (95% CI 0.05 to 6.74)). In transancestral meta-analysis
of 75 genetic variants assessed in EA, AA, AS and HS (see
online supplementary ﬁgure S1 and table S1), the strongest asso-
ciation signal was detected at rs1876453 (p=4.2×10−4, OR
0.85) and only this signal reached the Bonferroni-corrected sig-
niﬁcance level (p<6.7×10−4).
Increased signal associated with rs1876453 after
subphenotype stratiﬁcation
We next assessed the association of rs1876453 with 14 lupus
subphenotypes. In case controls, the minor allele was consist-
ently associated with decreased risk of serositis, renal disorder,
haematological disorder and dsDNA autoantibodies in EA, AA
and HS, of which the strongest association was detected
with dsDNA autoantibodies (pEA=6.6×10
−4, OR 0.73 (95% CI
0.61 to 0.88); pAA=9.7×10
−3, OR 0.72 (95% CI 0.56 to
0.92); pHS=7.1×10
−3, OR 0.58 (95% CI 0.39 to 0.86);
pmeta=7.6×10
−7, OR 0.71) (table 1). In cases only, the minor
allele of rs1876453 was associated with decreased risk of
dsDNA autoantibodies (pmeta=1.9×10
−4, OR 0.75) and renal
disorder (pmeta=1.3×10
−2, OR 0.83) (table 1), but only the
association with dsDNA autoantibodies remained signiﬁcant
after correction for multiple comparisons.
rs1876453 tags the protective EA haplotype
No other SNP in this region exhibited stronger association with
dsDNA autoantibodies in EA, AA and HS than rs1876453
Figure 2 Allele-speciﬁc effects of rs1876453 on CR1 and CR2 expression. Relative amounts of CR2 (A) or CR1 (C) RNA transcripts in primary B
cells from 35 or 40 healthy donors respectively were measured by qPCR using the comparative Ct method.17 Levels of surface CR2 (B) and CR1 (D)
on primary B cells from 131 healthy donors were determined by quantitative ﬂow cytometry (ABC, antibody binding capacity). Each point represents
a unique subject, and the line and error bars represent the mean SD for each group; p values were determined using a two-tailed Student t test,
and a p value of <0.05 was considered signiﬁcant. (E) Levels of surface CR1 and CR2 were plotted and subjected to correlation analysis and linear
regression. Each point represents a unique subject (minor allele, squares; major allele, triangles) and the lines represent the line of best ﬁt for each
allele (minor allele, dashed line; major allele, solid line). (F) Levels of surface CR1 and CR2 were also used to calculate the ratio of CR1 to CR2. Each
point represents a unique subject, and the line and error bars represent the mean±SD for each group; p values were determined using a two-tailed
Student t test and a p value of <0.05 was considered signiﬁcant.
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(ﬁgure 1A–C, see online supplementary table S2). When condi-
tioning on rs1876453, the association signals at all other SNPs
were eliminated (see online supplementary table S2). The H1
haplotype, constructed using rs1876453 and previously asso-
ciated or tightly linked CR2 SNPs, was equivalent to the pro-
tective EA SLE haplotype8 and was perfectly tagged in EA by
the minor allele of rs1876453 (ﬁgure 1D). In all three ancestral
groups, it was associated with decreased risk of SLE




The minor allele at rs1876453 is associated with altered
expression of B cell CR1
We did not detect allele-speciﬁc differences in CR2 mRNA or
protein levels in primary B cells from healthy controls
(ﬁgure 2A, B). However, CR1 mRNA and protein levels were
signiﬁcantly higher in subjects with the minor A allele (ﬁgure
2C, D). Although B cell CR1 and CR2 levels were positively
correlated in both groups (major allele Spearman r=0.6342,
p<0.0001; minor allele Spearman r=0.7998, p<0.0001, ﬁgure
2E), the ratio of CR1 to CR2 on B cells was higher in subjects
with the minor allele (p=0.0002; ﬁgure 2F). Allele-speciﬁc
differences in CR1 expression were not detected on other per-
ipheral blood cells (see online supplementary ﬁgure S2). These
data suggest that rs1876453 has long-range effects on the regu-
lation of expression of CR1, which lies directly 30 of CR2, that
are either B cell-speciﬁc or dependent on coexpression of CR2.
The minor allele at rs1876453 alters transcription factor
binding
rs1876453 is 97 nucleotides from the 50 end of the ﬁrst intron
of CR2. This ∼12 kb intron contains a conserved silencing
domain that controls CR2 expression in a cell type-speciﬁc and
developmentally regulated manner.19–22 The ENCyclopedia Of
DNA Elements (ENCODE) database23 reports the in vivo inter-
action of the region surrounding rs1876453 with multiple tran-
scription factors in B cells, including Pax5, Oct2 and CTCF
(ﬁgure 3). We conﬁrmed the formation of multiple
protein-DNA complexes containing the sequence surrounding
rs1876453 by electrophoretic mobility shift assay (EMSA) using
NE from several cell lines (K562, erythroid, CR1+CR2−; Reh,
pre-B, CR1+CR2−; Ramos, mature B, CR1+CR2+, see online
supplementary ﬁgure S3). In the presence of the minor A allele
at rs1876453, transcription factor binding was reduced or
Figure 3 The ENCyclopedia Of DNA Elements (ENCODE) Project data surrounding rs1876453. (A) The ﬁrst exon and 50 end of the ﬁrst intron of
the CR2 gene. The 5’ untranslated region (50 UTR) is shown before the methionine start codon, in green. These data are derived from the University
of California Santa Cruz (UCSC) Genes Track. (B) The location of rs1876453 (highlighted in yellow) and previously reported systemic lupus
erythematosus-associated rs3813946 (in blue font). These data are derived from the Common Single-Nucleotide Polymorphisms (SNP) (138) Track
(ft.ncbi.nih.gov/snp).39 (C) DNaseI hypersensitive sites in the GM12878 Epstein–Barr virus (EBV)-transformed B cell line and in primary CD20+
B cells derived by DNase-seq. These data are derived from the UCSC Uniform DNaseI HS Track. Signal values are shown as grayscale-coloured items
where higher signal values correspond to darker-coloured blocks. Primary B cells contain an additional hypersensitivity site that overlies rs1876453.
(D) Histone marks surrounding rs1876453, as determined by chromatin immunoprecipitation (ChIP)-seq. These data were derived from the Layered
H3K4Me3, H3K4Me1 and H3K27Ac Tracks. The H3K4Me3 histone mark is associated with poised or active promoters, the H3K4me1 histone mark is
associated with enhancers and with DNA regions downstream of transcription sites and the H3K27Ac histone mark may enhance transcription by
blocking the spread of the repressive histone mark H3K27Me3. Data shown are for the GM12878 EBV-transformed B cell line. (E) Transcription
factor binding sites determined by ChIP-seq are shown as grey boxes that encompass the peaks of transcription factor occupancy, with the darkness
of the box proportional to the maximal signal strength observed in any cell line. The name to the left of the box is the transcription factor, and
includes in parentheses the antibody used for ChIP. The letters to the right of the box indicate the cell lines in which a signal is detected, with the
darkness of the letter proportional to the signal strength in the cell line. Data are derived from the Transcription Factor ChIP Track. CCCTC-binding
factor (CTCF) binding was seen in multiple EBV-transformed B cell lines (G, g) as well as a variety of other cell lines. (F) CTCF binding to primary
CD20+ B cells by ChIP-seq. Peak occupancy lies over exon 1 and the 50 UTR. Data are derived from the Broad Histone Track. (G) Transcription levels
for several cell types assayed by high-throughput sequencing of polyadenylated RNA (RNA-seq). Each cell line is associated with a particular colour;
the GM12878 cell line is shown in pink. This ﬁgure was obtained from the UCSC Genome Browser (Human Feb 2009 (GRCh37/hg19) Assembly;
http://genome.ucsc.edu).40
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ablated and less cold competitor was required to out-compete
protein-DNA complexes (ﬁgure 4A). Addition of an antibody to
CTCF blocked the formation of complex C (ﬁgure 4B), and
speciﬁc enrichment of the region surrounding rs1876453 was
three-fold higher in the presence of the major allele by
ChIP-PCR (p=0.0178; ﬁgure 5A–D), suggesting that CTCF
binds the region surrounding rs1876453 in an allele-speciﬁc
manner. CTCF abundance was comparable between the two cell
lines (ﬁgure 5E), and transcript abundance of CR1 relative to
CR2 was higher in the cell line homozygous for the minor allele
(p=0.023; ﬁgure 5F), consistent with the data from primary B
cells.
DISCUSSION
The minor allele of rs1876453, located in intron 1 of CR2, was
associated with decreased risk of lupus in three of four ancestral
groups studied, with the strongest association when cases were
stratiﬁed based on the presence of dsDNA autoantibodies. This
allele altered the formation of multiple DNA-protein complexes,
including one containing CTCF, which has been termed the
master regulator of chromatin organisation. Furthermore, it was
associated with increased B cell expression of CR1, suggesting
long-range effects of rs1876453 on gene regulation and provid-
ing a plausible mechanism by which it may alter lupus
susceptibility.
We previously identiﬁed the SLE-associated haplotype tagged
by the minor allele of rs1876453 (H1 as shown in ﬁgure 1D) in
EA,8 and show here that it is found also in AA and HS
(ﬁgure 1D). Although it is difﬁcult to prove that a SNP is causal
based on association testing, our transancestral study, which ana-
lysed a high density of SNP markers and capitalised on the weak
linkage disequilibrium around rs1876453 in AA (ﬁgure 1B),
provides compelling evidence that rs1876453 rather than the
previously identiﬁed SNPs (rs3813946, rs1048971, rs17615
and rs4308977) or SNPs tightly linked to rs1876453 in EA
(rs17258955 and rs61821130 in intron 1, rs61735651 in exon
14 and rs7549152 in intron 15) best explains the association
signal. Modest association signals of rs1876453 increased after
stratiﬁcation of subjects based on speciﬁc clinical manifestations
of lupus, with the strongest signals in the case-control analysis
when subjects were stratiﬁed based on the presence of dsDNA
autoantibodies. Although increased signals were seen with other
Figure 4 Allelic differences in complex formation at rs1876453. (A) Protein-DNA complexes (indicated by arrows; A–D) were formed with
oligonucleotides including either the minor A or major G allele in the absence or presence of K562 (Lanes 1–10), Reh (Lanes 11–20) and Ramos
(Lanes 21–30) nuclear extracts. Speciﬁcity and binding afﬁnity of the protein-DNA complexes were demonstrated by the addition of 15-molar to
60-molar excess of unlabelled oligonucleotides. UB represents unbound control. (B) Anti-CTCF (CCCTC-binding factor) antibody was included during
the formation of protein-DNA complexes to determine whether CTCF was involved in forming these complexes. Data shown are representative of at
least three independent experiments.
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clinical manifestations, only dsDNA autoantibodies were signiﬁ-
cantly associated in both case-control and case-only analyses,
suggesting that rs1876453 has a preferential effect on the pro-
duction or presence of dsDNA autoantibodies. The mechanism
underlying this dsDNA speciﬁcity is unclear, and characterising
it will lead to a greater understanding of the etiopathogenesis of
lupus, since dsDNA autoantibodies are highly speciﬁc for SLE
(reviewed in refs24 25), and can predict onset and exacerbation
of disease.26–28 Anti-dsDNA antibody levels in the serum of
genotyped patients with SLE did not correlate with rs1876453
genotype (data not shown), but therapy and other
disease-related factors may obscure an association. Future
studies with longitudinal analyses of patients will address this
more stringently.
rs1876453 is located in a transcriptional regulatory region
deﬁned by DNase hypersensitivity and containing histone marks
associated with active enhancers (H3K27ac, H3K4me1 and
H3K4me3) (ﬁgure 3). We demonstrated that the minor allele at
rs1876453 alters the formation of multiple protein-DNA com-
plexes (ﬁgure 4A) and that CTCF is a component of one of
these complexes (ﬁgures 4B and 5). CTCF, a highly conserved
and ubiquitously expressed zinc ﬁnger protein, is a master regu-
lator of genome spatial organisation that mediates chromatin
loops within the genome.29 By binding to insulators and bound-
ary elements, it demarcates chromatin into regulatory regions
and blocks communication between promoters and enhancers to
regulate gene expression. CTCF interacted with the region sur-
rounding rs1876453 in both lymphoblastoid B cell lines and
Figure 5 CCCTC-binding factor (CTCF) interacts with CR2 intron 1 in vivo and demonstrates differential afﬁnity for rs1876453 alleles. (A)
Chromatin immunoprecipitation performed using an antibody speciﬁc for CTCF yielded allele-speciﬁc enrichment of the region surrounding
rs1876453 from Epstein–Barr virus (EBV)-transformed B cells homozygous for the major or minor allele at rs1876453. The qPCR products were
visualised by ethidium bromide staining of a 1.8% agarose gel and sized using a PCR marker (New England Biolabs). A non-speciﬁc IgG control
(IgG) and a control without antibody (No Ab) were included to measure background enrichment. Decreasing amounts of enrichment were observed
with serially diluted input samples (Lanes 5–8; 13–16). NTC, no template control. (B) A representative qPCR ampliﬁcation plot. (C) The percentage
enrichment at the CR2 promoter was determined by quantiﬁcation against the standard curve. CTCF enrichment was normalised to the background
enrichment generated by a non-speciﬁc IgG. (D) CTCF enrichment normalised to the minor allele at rs1876453. (E) CTCF transcript abundance for
each homozygous cell line after normalisation to β-actin. (F) Transcript abundance of CR1 relative to CR2 in each homozygous cell line, with each
transcript normalised to β-actin. Data shown are the mean±SEM for three independent experiments.
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primary B cells,23 with peak occupancy directly over rs1876453
(ﬁgure 3), and our data demonstrate an allele-dependent effect
on its binding in vivo (ﬁgure 5) with less binding of CTCF to
the minor A allele, which is associated with higher CR1 expres-
sion and is protective, and more binding to the major G risk
allele, which is associated with lower CR1 expression. These
data suggest that CTCF may have a repressive effect on CR1
transcription when bound to this locus. Efforts to identify the
other transcription factors differentially binding this region as a
result of the allele at rs1876453 are currently underway.
CR1 expression was increased in B cells of subjects harbour-
ing the minor allele at rs1876453 at both the mRNA and
protein level (ﬁgure 2). Eukaryotic transcription is tightly con-
trolled by regulatory elements that, though perhaps distant from
their target genes, can be brought into close proximity with the
general transcriptional machinery at transcription start sites
through the formation of chromatin loops.30 Therefore, altered
CTCF binding at intron 1 of CR2 may directly affect CR1 tran-
scription via alterations in the chromatin looping that regulates
these genetic regions. Alternatively, CR1 expression may be
modiﬁed indirectly by regulatory RNA generated from intronic
CR2 sequences. The minor allele at rs1876453 introduces a
cryptic splice acceptor site (consensus value (CV) 71.05, CV
variation of mutant from wild type 68.75%) and is predicted to
break splice enhancer and silencer motifs (Human Splicing
Finder31). Although there are no known microRNA sequences
in the ﬁrst intron of CR2, several expressed sequence tags have
been aligned to this region in B cells32 and the ENCODE
project has determined that it is actively transcribed (ﬁgure 3).
CR1 binds C3b and C4b activation fragments and is physic-
ally associated with CR2 on B cells.33 Although it has an inde-
pendent negative regulatory role in B cell receptor
(BCR)-mediated B cell activation,34 it also acts as a cofactor for
the Factor I-mediated cleavage of C4b to iC4b and of C3b to
iC3b and C3dg. iC3b and C3dg are speciﬁc ligands for CR235
that either augment or inhibit signalling through the BCR in
mature B cells,36 37 depending on ligand valency. Strength of
BCR signalling may also affect tolerance induction in tran-
sitional B cells.38 Therefore, we hypothesise that increased
expression of CR1 associated with rs1876453, in individuals
susceptible to lupus, may tolerise transitional or arrest mature
dsDNA-speciﬁc B cells that encounter complement-coated apop-
totic debris and, as a consequence, modify the initiation or
course of lupus.
In sum, we show that the minor allele at rs1876453 reduces
risk of lupus and that this effect is due, in part, to increased
expression of CR1 on B cells. Since this allele alters binding of
transcription factors with long-range effects, allelic variation at
this SNP may modify expression of additional genes involved in
lupus pathogenesis. Given the common association of
rs1876453 across ancestral groups, further investigation of its
mechanisms and effects has broad implications for the manage-
ment of patients with this disease.
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